glp 1 glp 2 dual agonist signaling GLP-1-based therapies for type diabetes: from single, and triple Tirzepatide (LY3298176) is a Dual

this association does not imply causation

Mathur, R., Alexander, C

Barreto-Vianna AR, Aguila MB, Mandarim-de-Lacerda CA

The latest FDA draft guidance for developing drugs and biological products for weight reduction, published in January 2025, references the effect of AOMs on body composition and recommends measuring it, however, it does not consider the typical loss of lean mass harmful [1]

Obesity is associated with increased basal and postprandial -cell insulin secretion even in the absence of insulin resistance

One of the most promising options for weight loss is GLP-1, originally developed for type 2 diabetes but now gaining attention for its potential in nondiabetic patients